Did the 2020 UN vote legalise cannabis internationally?

No. The December 2020 CND vote removed cannabis from Schedule IV of the 1961 Single Convention — the most restrictive classification — but cannabis and cannabis resin remain listed under Schedule I. Member states still have treaty obligations under Schedule I, and domestic legalisation or access decisions are made through each country's own legislation and regulatory framework.

Why was cannabis placed in Schedule IV of the 1961 Convention in the first place?

The 1961 scheduling reflected the political consensus of the era, shaped largely by decades of US-driven prohibition politics. The pharmacology of cannabis was not well understood at the time — THC wasn't even characterised until 1964, three years after the treaty was signed, and the endocannabinoid system wasn't described until the late 1980s and early 1990s.

How does the UN scheduling framework relate to Australia's Poisons Standard?

Australia's domestic scheduling — set by the TGA through the Poisons Standard — is informed by but not automatically dictated by UN treaty obligations. The Narcotic Drugs Act 1967 reflects Australia's Single Convention commitments, but specific scheduling decisions (such as placing THC-containing products under Schedule 8) are made through domestic regulatory processes, not directly by the CND vote.

What did the WHO's Expert Committee on Drug Dependence recommend in 2019?

The WHO's ECDD published six recommendations to the CND in 2019 following a comprehensive review. Key recommendations included removing cannabis from Schedule IV of the 1961 Convention (while retaining Schedule I listing), and clarifying that CBD preparations without significant THC content did not warrant international scheduling. Five of the six recommendations were adopted by the CND in December 2020.

UN Scheduling of Cannabis

By Hannah Bui · 24 June 2026 · 7 min read

Grand building with columns and flags under blue sky

Sixty-three years ago, delegates in New York signed a treaty that would shape cannabis policy for the rest of the twentieth century and well into the twenty-first. The 1961 Single Convention on Narcotic Drugs placed cannabis , flower, resin, and extracts , into Schedule IV alongside heroin. Schedule IV was reserved for substances deemed to have "particularly dangerous" properties and "little or no therapeutic value." That's the framing that stuck, in international law, for nearly six decades.

I find the history of drug scheduling genuinely fascinating from a research-literacy angle, because it's a masterclass in how policy can calcify around evidence that was, at the time, thin , and then resist revision long after the evidence landscape has changed. Let's be careful with that claim, though: the story is more tangled than a simple "bad science, bad law" narrative.

What the Single Convention actually established

The 1961 Single Convention on Narcotic Drugs, administered through the United Nations Office on Drugs and Crime (UNODC), created four schedules. Schedule I covered substances with addiction potential requiring international control measures. Schedule IV; the most restrictive, was a subset of Schedule I for substances judged to be especially dangerous with negligible therapeutic use. Cannabis and cannabis resin were listed in both Schedule I and Schedule IV simultaneously.

This dual listing had real-world consequences. It obligated signatory nations to restrict cultivation, trade, and use. It did not technically prohibit domestic policy flexibility, but it created enormous political and legal pressure on member states to maintain prohibition. Australia, as a signatory, built its domestic scheduling framework partly in dialogue with these international obligations, which is one reason understanding the UN layer helps make sense of our own Poisons Standard.

The 1971 Convention on Psychotropic Substances extended a similar logic to synthetic drugs, and the 1988 UN Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances added further enforcement architecture. Together, these three treaties form the backbone of the international drug control system.

The WHO's role; and the gap between review and action

Scheduling decisions under the Single Convention are formally recommended by the World Health Organization's Expert Committee on Drug Dependence (ECDD) and then voted on by the UN Commission on Narcotic Drugs (CND). The WHO makes the scientific assessment; the CND, a political body, decides whether to act on it.

That separation matters. The WHO's ECDD had reviewed cannabis multiple times across the decades, but a comprehensive, dedicated review didn't come until 2019, when the committee published a set of six recommendations to the CND. These included removing cannabis and cannabis resin from Schedule IV of the 1961 Convention (while keeping them in Schedule I), and clarifying the status of cannabidiol (CBD) preparations. The ECDD found that CBD on its own; without significant tetrahydrocannabinol (THC), did not warrant international scheduling.

On 2 December 2020, the CND voted. Of the six recommendations, five passed. The headline one, removing cannabis from Schedule IV; passed narrowly, 27 votes to 25, with one abstention. It was the first change to cannabis scheduling under the Single Convention since 1961.

What the 2020 vote changed, precisely

Cannabis and cannabis resin remain in Schedule I of the 1961 Convention. The removal from Schedule IV means, in treaty terms, that the international community no longer formally classifies cannabis as having "particularly dangerous properties" with no therapeutic value. That's a symbolic and legal shift, but it doesn't automatically liberalise anything. Member states still have obligations under Schedule I, and domestic law continues to govern actual access.

For Australia, the more direct levers are the TGA's Poisons Standard and the legislative frameworks that sit under it. Schedule 8 (Controlled Drug) status for medicinal cannabis products containing THC reflects domestic policy decisions informed by, but not mechanically dictated by, the UN framework. The Special Access Scheme and the Authorised Prescriber pathway, which Australia has used to permit legal prescribing of medicinal cannabis since 2016, exist within our own regulatory architecture. The UN vote mattered for international signalling; Australian patients and prescribers operate under TGA rules.

Honestly, I think the 2020 vote gets over-interpreted in both directions. Some outlets called it a "landmark legalisation." It was not. Others dismissed it as meaningless. That's too cynical; removing the Schedule IV designation does shift the legal and diplomatic landscape for member states wanting to reform, because they no longer have to argue against the treaty's harshest classification. It clears one obstacle, not all of them.

The science that wasn't available in 1961

The 1961 scheduling happened before the structure of THC had even been characterised. Raphael Mechoulam's group in Israel identified and synthesised THC in 1964, three years after the Single Convention was signed. The endocannabinoid system itself wasn't described until the late 1980s and early 1990s, with the identification of the CB1 receptor in 1988 and anandamide in 1992.

This is the part I come back to when I'm thinking about how to read the history without getting the narrative wrong. The 1961 delegates weren't ignoring robust science. The science largely didn't exist yet. What they were doing was codifying the political consensus of that moment, which was shaped by prior decades of prohibition politics, particularly the trajectory of US domestic drug policy from the 1930s onward.

Between sea swims last winter I went back through some of the original WHO expert committee reports from the 1950s and early 1960s. The reasoning is notably thin by modern standards. The cannabis entries lean heavily on assessments of "abuse potential" and social harm, with very limited pharmacological analysis. That's not a criticism of the people involved so much as an observation about the state of the field. Nobody in 1961 had the tools to characterise how CBD differs mechanistically from THC, or what the CB2 receptor does in peripheral tissue.

What happened between 1961 and 2020

The decades between the Single Convention and the 2020 CND vote weren't static. Several member states; the Netherlands from the 1970s, then a wave of US states from the 1990s, then Canada's federal legalisation in 2018, moved domestically without formally challenging the treaty framework. The legal mechanism they used was largely tolerance policies and later domestic legislation that existed in tension with, rather than outright violation of, their treaty obligations. Treaty law scholars have written at length about this ambiguity.

The WHO's ECDD reviews between 1961 and 2019 were more limited in scope. A notable 2003 WHO report on cannabis found no evidence to support the Schedule IV classification but stopped short of a formal rescheduling recommendation. That gap between scientific assessment and formal action is itself an interesting study in how international institutions work, or don't.

Uruguay became the first country to fully nationalise cannabis production and retail in 2013. Canada followed in 2018. Neither formally withdrew from the Single Convention; both accepted they were operating in legal tension with it. The 2020 vote reduced that tension for Schedule IV specifically, though Schedule I obligations remain.

Australia's domestic scheduling in context

When Australia legalised the cultivation and supply of medicinal cannabis in 2016, it did so through amendments to the Narcotic Drugs Act 1967 and the Therapeutic Goods Act 1989, alongside TGA scheduling changes. The Narcotic Drugs Act 1967 is itself partly shaped by Australia's Single Convention obligations; so the international and domestic frameworks are genuinely entangled, not parallel.

Products containing THC above specified thresholds sit under Schedule 8 in the Poisons Standard. Lower-THC preparations and CBD at certain concentrations have separate scheduling pathways. None of this changed automatically because of the 2020 UN vote; each change required specific domestic regulatory action by the TGA.

For anyone reading research on cannabis and trying to understand why certain compounds were or weren't studied prior to the 2000s, the scheduling history is relevant context. Cannabis's placement in the most restrictive international category created real barriers to research, controlled-drug licensing requirements, limited supply of standardised research-grade material, and the political climate around funding. Those barriers haven't disappeared, but the landscape has shifted considerably since 2016 in Australia and since 2020 internationally.

The short version is: the 2020 CND vote was the first significant change to international cannabis scheduling in nearly sixty years, and it mattered. It also didn't resolve most of the practical policy questions, which are decided country by country. Understanding where the international framework came from, and what it actually says; is the first step to reading the policy debate clearly.

Sources

, Hannah Bui, Evidence & research-literacy writer

]]>

Common questions

Did the 2020 UN vote legalise cannabis internationally?: No. The December 2020 CND vote removed cannabis from Schedule IV of the 1961 Single Convention — the most restrictive classification — but cannabis and cannabis resin remain listed under Schedule I. Member states still have treaty obligations under Schedule I, and domestic legalisation or access decisions are made through each country's own legislation and regulatory framework.
Why was cannabis placed in Schedule IV of the 1961 Convention in the first place?: The 1961 scheduling reflected the political consensus of the era, shaped largely by decades of US-driven prohibition politics. The pharmacology of cannabis was not well understood at the time — THC wasn't even characterised until 1964, three years after the treaty was signed, and the endocannabinoid system wasn't described until the late 1980s and early 1990s.
What is the difference between Schedule I and Schedule IV under the 1961 Single Convention?: Schedule I covers substances with addiction potential requiring international controls on manufacture, trade, and possession. Schedule IV is a subset of Schedule I reserved for substances judged to be especially dangerous with little or no therapeutic value. Cannabis was listed in both simultaneously from 1961 until December 2020, when it was removed from Schedule IV while remaining in Schedule I.
How does the UN scheduling framework relate to Australia's Poisons Standard?: Australia's domestic scheduling — set by the TGA through the Poisons Standard — is informed by but not automatically dictated by UN treaty obligations. The Narcotic Drugs Act 1967 reflects Australia's Single Convention commitments, but specific scheduling decisions (such as placing THC-containing products under Schedule 8) are made through domestic regulatory processes, not directly by the CND vote.
What did the WHO's Expert Committee on Drug Dependence recommend in 2019?: The WHO's ECDD published six recommendations to the CND in 2019 following a comprehensive review. Key recommendations included removing cannabis from Schedule IV of the 1961 Convention (while retaining Schedule I listing), and clarifying that CBD preparations without significant THC content did not warrant international scheduling. Five of the six recommendations were adopted by the CND in December 2020.